The present disclosure provides for cryopreservation compositions and methods for cryopreserving biological materials using red blood cells (RBCs) to improve cell viability. RBCs loaded on the surface with target specific antibodies will allow modified RBCs in close proximity to target cells and will provide the benefits of RBC properties to target cryopreserving cell population. Furthermore. target specific antibody conjugated RBCs will be loaded with cryoprotectant molecules such as trehalose (type of sugar molecules) alone or in combination with free radical scavengers like catalases. glutathione peroxidase. superoxide dismutase (SOD), -tocopherol (Vit. E). ascorbic acid (Vit. C). carotene (Vit. A), selenium to further improve the recovery of cells post cryopreservation.

The current disclosure describes simplified methods of preparing cells for patient infusion where the simplified methods result utilize less steps than conventional methods, decreasing required manipulation steps and reducing the time between beginning of cell manipulation for administration and ultimate administration to a patient. Methods of cryopreserving, thawing, and diluting cells and kits for practicing the methods are also provided herein.

Provided is a method for producing a transplant material that allows a foreign substance to be injected easily into an organ removed from an animal body. Also provided is a transplant material that undergoes reduced damage despite a foreign substance being injected. The present invention is a method for producing a transplant material containing an organ into which a foreign substance is injected, the method including a step for bringing at least a portion of an organ removed from an animal body into contact with a plastic member to carry out positioning, and a step for injecting a foreign substance into the positioned organ.

The purpose of the present invention is to provide spermatozoa having high motility. The present invention is a composition for treating sperm that comprises a mesenchymal stem cell culture supernatant. The composition for spermatozoa treatment of the present invention is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Furthermore, mesenchymal stem cells in the mesenchymal stem cell culture supernatant comprised in the composition for treating sperm are preferably derived from adipose tissue, derived from umbilical cord tissue, or derived from bone marrow tissue.

The present disclosure relates to a method for preserving free cells, such as blood cells, by freezing in the presence of a nontoxic cryoprotectant, i.e., one that can be administered to a living human or animal organism. The present disclosure thus relates to methods, compositions and kits for freezing and storing non-adherent cells, such as red blood cells, for extended periods of time while preventing the lesions that can occur during the storage thereof and, in the case of red blood cells, while preserving deformability and increasing survival.

A method for establishing a seed cell bank of mesenchymal stem cells (MSC), which belongs to the technical field of stem cell culture. The method includes: mixing a plurality of P2 generation (Pn1 generation) MSCs from different donor sources for culturing.

A method for transporting a biological sample at hypothermic temperatures. The container can be cooled using phase change material and pump fluid through the sample. The fluid can pump through the system at a rate independent of the parameters of the biological sample. A valve can control the rate of flow of the fluid into the biological sample.

Provided herein are methods for deactivation of effector cells, such as NK cells, including cells for adoptive cell therapy that are off-the-shelf cells. The deactivated cells may be cryopreserved following deactivation. The deactivated and cell may be expanded and/or activated prior to deactivation, and may or may not comprise a transgene, which may optionally encode a chimeric antigen receptor and/or T cell receptor. In certain embodiments, disclosed are methods for deactivation of NK cells comprising treatment with a kinase inhibitor, for example an mTOR inhibitor and/or a tyrosine kinase inhibitor, for example rapamycin and/or Dasatinib. Also provided herein are deactivated and cryopreserved NK cells, and methods of preparing and/or using the same for treatment of a subject in need thereof, for example treatment of a subject with cancer.

Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.

Provided is a method for storing or transporting renal cells that have a high cell viability, maintain a physiological function of the kidney, and can be used as a drug evaluation system, at a temperature lower than a culture temperature. An aspect of the present invention is a method for storing or transporting renal cells, the method including a maintenance step of managing a liquid containing aggregates of the renal cells to a temperature that is a maintenance temperature and lower than a culture temperature of the renal cells and at which the liquid is not frozen.